Skip to main content

Building a leading microbiome company in oncology

We are a clinical-stage microbiome therapeutics company aiming to
improve survival in cancer.

See News

Corporate profile

We are a clinical-stage microbiome therapeutics company aiming to restore and modulate patient-microbiome symbiosis to improve survival in cancer. To do so, we are developing a novel class of microbiome drug candidates: Microbiome Ecosystem Therapies (MET). MET are high-diversity, high-richness, indication-specific products aiming to leverage the full functional diversity of a microbiome ecosystem. Our MET drug development platform leverages gutPrint®, our proprietary AI-based computational biology and our proprietary cGMP manufacturing capacities to deliver innovative new drugs for the treatment of graft-vs-host-disease , the prevention of complications of HSCT for patients with liquid tumors and the improvement of response to immune checkpoint inhibitors in solid tumors. Our team combines expertise ranging from microbiology to data science to oncology and benefits from the commitment of world-leading scientists.

Press Releases

Press Releases

August 10, 2022: MaaT Pharma Announces Update on U.S. FDA Investigational New Drug Application for MaaT013 in Patients with Acute Graft-versus-Host Disease

MaaT Pharma Announces Update on U.S. FDA Investigational New Drug Application for MaaT013 in Patients…
Press Releases
August 01, 2022: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital
Press Releases
July 28, 2022: MaaT Pharma Reports Cash and Revenues for Q2 2022
Press Releases
July 6, 2022: MaaT Pharma Announces the Availability of the 2021 Universal Registration Document
Press Releases
June 2, 2022: MaaT Pharma Confirms Positive Results from Completed Phase 1b CIMON Study Evaluating MaaT033 in Blood Cancer Patients

See more

Media Coverage

Media

July 2022: MaaT Pharma featured in MedNous

Interview of Hervé Affagard published in the July-August 2022 edition of MedNous, a business-science publication…
Media
June 27, 2022: The microbiome revolution – presentation of Dr. Joël Doré
Media
June 13, 2022: MaaT Pharma in the top 3 biotechs to watch – Le Revenu (Article in French)
Media
April 11, 2022: Interview of Hervé Affagard in Journal des biotechs – Boursorama
Media
April 8, 2022: Interview of Hervé Affagard in Boursier in French
Media
April 8, 2022: Article in French – MaaT Pharma launches its Phase 2a clinical trial in melanoma

See more

Posters

Videos

MaaT Pharma dans les médias MaaT Pharma in the News